doi: 10.1016/j.scienta.2020.109215 120 KumarY.SajwanP.UniyalS.MishraA
The Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) phase 3 programme demonstrated the efficacy of oral semaglutide versus placebo and active comparators (including empagliflozin, sitagliptin and liraglutide) in achieving glycaemic control and weight loss, with a safety profile consistent with the GLP-1RA drug class [10,11,12,13,14,15,16,17,18,19,20,21]
Statistical analysis Data were subjected to one-way ANOVA analysis, followed by Dunnetts multiple comparison test
For long-term storage, maintain at or below -20C to preserve peptide stability and research viability
Post-Meal Injection: Comfort and Consistency Benefits Injecting semaglutide after eating may offer psychological comfort to some patients, particularly those who experience injection-site anxiety or mild nausea
Notably, modified short peptides have improved bio-functions compared with those in the original analogs, and are of great promise in modern biomedicine thanks to recent advances in science and biotechnology [22]
